Advanced search
Publication Cover
Leukemia & Lymphoma Volume 48, 2007 - Issue 8
Submit an article Journal homepage
155
Views
11
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Evaluation of the MDR1, ABCG2, Topoisomerases IIα and GSTπ gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen

Dr. Sara Galimberti Department of Oncology, Transplants and Advances in Medicine, Hematology Section, University of Pisa, ItalyCorrespondence[email protected]
,
Balint Nagy Genetic Laboratory, First Department of Obstetrics and Gynaecology, Semmelweis University, Budapest, Hungary
,
Edoardo Benedetti Department of Oncology, Transplants and Advances in Medicine, Hematology Section, University of Pisa, Italy
,
Simone Pacini Department of Oncology, Transplants and Advances in Medicine, Hematology Section, University of Pisa, Italy
,
Stefania Brizzi Department of Oncology, Transplants and Advances in Medicine, Hematology Section, University of Pisa, Italy
,
Francesco Caracciolo Department of Oncology, Transplants and Advances in Medicine, Hematology Section, University of Pisa, Italy
,
Federico Papineschi Department of Oncology, Transplants and Advances in Medicine, Hematology Section, University of Pisa, Italy
,
Elena Ciabatti Department of Oncology, Transplants and Advances in Medicine, Hematology Section, University of Pisa, Italy
,
Francesca Guerrini Department of Oncology, Transplants and Advances in Medicine, Hematology Section, University of Pisa, Italy
,
Rita Fazzi Department of Oncology, Transplants and Advances in Medicine, Hematology Section, University of Pisa, Italy
,
Martina Canestraro Department of Oncology, Transplants and Advances in Medicine, Hematology Section, University of Pisa, Italy
&
Mario Petrini Department of Oncology, Transplants and Advances in Medicine, Hematology Section, University of Pisa, Italy
 show all
Pages 1502-1509 | Received 12 Nov 2006, Accepted 06 Apr 2007, Published online: 01 Jul 2009

References

  • Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36: 69–86
  • Campo E, Raffeld M, Jaffe E S. Mantle-cell lymphoma. Semin Hematol 1999; 36: 115–127
  • Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol 2002; 29(1 Suppl 2)56–69
  • Pott C, Scharder C, Bruggemann M, Ritgen M, Harder L, Raff T, et al. Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease. Eur J Haematol 2005; 74: 353–358
  • Vigouroux S, Gaillard F, Moreau P, Harousseau J L, Milpied N. High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica 2005; 90: 1580–1582
  • Zhu Y, Hollmen J, Raty R, Aalto Y, Nagy B, Elonen E, et al. Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br J Haematol 2002; 119: 905–915
  • Thieblemont C, Nasser V, Felman P, Leroy K, Gazzo S, Callet-Bauchu E, et al. Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 2004; 103: 2727–2737
  • Giesler F, Glasmacher A, Kampfe D, Wandt H, Nuessler V, Valsamas S, et al. Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines. Leukemia 1996; 10: 1177–1180
  • Bennaceur-Griscelli A, Bosq J, Koscielny S, Lefrere F, Turhan A, Brousse N, et al. High level of glutathione-S-transferase pi expression in mantle cell lymphomas. Clin Cancer Res 2004; 10: 3029–3034
  • Doyle L A, Ross D D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22: 7340–7358
  • Galimberti S, Guerrini F, Palumbo G A, Consoli U, Fazzi R, Morabito F, et al. Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leuk Res 2004; 28: 367–372
  • Juranka P, Zastawny R, Ling V. P-glycoprotein: multidrug resistance and a superfamily of membrane associated transport proteins. FASEB J 1989; 3: 2582–2585
  • Romaguera J E, Fayad L, Rodriguez M A, Broglio K R, Hagemeister F B, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013–7023
  • Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253
  • Galimberti S, Brizzi F, Mameli M, Petrini M. An advantageous method to evaluate IgH rearrangement and its role in minimal residual disease detection. Leuk Res 1999; 10: 921–929
  • van Dongen J J, Langerak A W, Bruggemann M, Evans P A, Hummel M, Lavender F L, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257–2317
  • The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
  • Perea G, Altes A, Bellido M, Aventin A, Bordes R, Ayats R, et al. Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL). Histopathology 2004; 45: 268–274
  • Maliepaard M, Scheffer G L, Faneyte I F, van Gastelen M A, Pijnenborg A C, Schinkel A H, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61: 3458–3464
  • Damaj G, Lefrere F, Delarue R, Varet B, Furman R, Hermine O. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 2003; 17: 1914–1915
  • Jazirehi A R, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24: 2121–2143

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.